<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794711</url>
  </required_header>
  <id_info>
    <org_study_id>CONCORD-B</org_study_id>
    <nct_id>NCT05794711</nct_id>
  </id_info>
  <brief_title>Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (CONCORD-B)</brief_title>
  <official_title>Concordance Between Intraoperative Frozen Section Pathology and Postoperative Paraffin-embedded Pathology in Diagnosing the IASLC Grade of Lung Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to confirm the concordance rate between intra-operative&#xD;
      frozen section pathological diagnosis and post-operative paraffin embedded pathological&#xD;
      diagnosis, and use this result to guide surgical treatment for early stage (cT1N0M0) lung&#xD;
      adenocarcinomas.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance rate</measure>
    <time_frame>2 years</time_frame>
    <description>Concordance rate between intraoperative frozen section and postoperative paraffin embedded pathology in making the diagnosis of IASLC grades of lung adenocarcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concordance rate</measure>
    <time_frame>2 years</time_frame>
    <description>Concordance rate between intraoperative frozen section and postoperative paraffin embedded pathology in making the diagnosis of lung adenocarcinoma subtypes according to the WHO classifications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance rate</measure>
    <time_frame>2 years</time_frame>
    <description>Concordance rate between intraoperative frozen section and postoperative paraffin embedded pathology in making the diagnosis of pleural invasion and lymph node invasion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance rate</measure>
    <time_frame>2 years</time_frame>
    <description>Concordance rate between intraoperative frozen section and postoperative paraffin embedded pathology in making the diagnosis of spread through air space (STAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival (RFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Recurrence-free survival (RFS) is defined as the time from date of curative surgery to the time of recurrence or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival (OS) is defined as the time from date of curative surgery to the time of death of any reason.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1063</enrollment>
  <condition>Lung Adenocarcinoma</condition>
  <condition>Surgical Procedure, Unspecified</condition>
  <condition>Pathology</condition>
  <arm_group>
    <arm_group_label>Clinical T1N0M0 lung adenocarcinoma patients eligible for surgery.</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection</intervention_name>
    <description>Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.</description>
    <arm_group_label>Clinical T1N0M0 lung adenocarcinoma patients eligible for surgery.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Clinical stage T1N0M0 lung adenocarcinoma patients who are going to undergo surgical&#xD;
        resection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who sign the informed consent form and are willing to complete the study&#xD;
             according to the study protocol;&#xD;
&#xD;
          -  No previous history of cancer or pulmonary surgery;&#xD;
&#xD;
          -  Solitary lesions or multiple lesions with only one not manifesting as pure&#xD;
             ground-glass opacity (GGO) on CT scan;&#xD;
&#xD;
          -  Peripheral clinical T1N0M0 patients that are eligible for surgery;&#xD;
&#xD;
          -  Non-small cell lung cancer is pathologically diagnosed before or at surgery;&#xD;
&#xD;
          -  No radiation therapy or chemotherapy before surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with clinical stages other than T1N0M0;&#xD;
&#xD;
          -  The lesion cannot be completely resected;&#xD;
&#xD;
          -  Previous history of cancer;&#xD;
&#xD;
          -  Patients having received radiation therapy or chemotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yue Zhao, M.D., Ph.D.</last_name>
    <phone>+86 18801735510</phone>
    <email>yuezhao97@outlook.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Haiquan, MD</last_name>
      <phone>+86-21 64175590</phone>
      <phone_ext>1707</phone_ext>
      <email>hqchen1@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 8, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Haiquan Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Intraoperative frozen section pathology</keyword>
  <keyword>Surgical treatment</keyword>
  <keyword>Lung adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

